Skip to Content

'
Andrew K. Lee, M.D., M.P.H.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Director of The Proton Therapy Center (PTC) www.mdanderson.org/patient-and-cancer-information/care-centers-and-clinics/specialty-and-treatment-centers/proton-therapy/index, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Program Director for Advanced Technologies Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Director, Proton Therapy Fellowship, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2000 Harvard School of Public Health, Boston, MA, MPH, Clinical Effectiveness
1999 Brigham and Women's Hospital, Harvard Medical School, Harvard School of Public Health, Boston, MA, MPH, Clinical Effectiveness
1996 University of Minnesota Medical School, Minneapolis, MN, MD, Medicine
1991 Amherst College, Amherst, MA, BA, Biology

Postgraduate Training

7/1997-7/2001 Clinical Residency, Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, Dr. Jay Harris, MD
6/1996-6/1997 Medical Internship, Good Samaritan Regional Medical Center, Phoenix, AZ, Dr. Alan Leibowitz

Board Certifications

1/2001 American Board of Radiology, Radiation Oncology

Experience/Service

Academic Appointments

Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 10/2007-present

Administrative Appointments/Responsibilities

Faculty Advisor, Department of Radiation Physics, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/2005-present

Institutional Committee Activities

Member, Faculty Appraisal Working Group, 2/2009-present
Member, Emergency Communications Subcommittee, 1/2009-present
Chair, Proton Therapy Center Clinical Operations, 1/2006-present
Faculty Senator, Faculty Senate, 1/2003-present
Member, Quality and Safety Council, 1/2001-present

Honors and Awards

2008-present Americas Top Doctors for Cancer, Castle Connolly Medical LTD
2007-present Guide to America's Top Oncologists, Consumers' Research Council of America

Selected Publications

Peer-Reviewed Original Research Articles
1. O'Daniel JC, Dong L, Zhang L, Wang H, Tucker SL, Kudchadker RJ, Lee AK, Cheung R, Cox JD, Kuban DA, Mohan R. Daily bone alignment with limited repeat CT correction rivals daily ultrasound alignment for prostate radiotherapy. Int J Radiat Oncol Biol Phys. In Press.
2. Fontenot JD, Lee AK, Newhauser WD. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys 74(2):616-22, 6/2009. PMID: 19427561.
3. Kudchadker RJ, Lee AK, Yu ZH, Johnson JL, Zhang L, Zhang Y, Amos RA, Nakanishi H, Ochiai A, Dong L. Effectiveness of Using Fewer Implanted Fiducial Markers for Prostate Target Alignment. Int J Radiat Oncol Biol Phys. e-Pub 5/2009. PMID: 19427750.
4. Frank SJ, Levy LB, Kuban DA, Lee AK, Kudchadker RJ, Bruno TL, van Vulpen M, Swanson DA. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy. J Urol 181(4). e-Pub 2/23/2009. PMID: 19233434.
5. Sejpal SV, Amos RA, Bluett JB, Levy LB, Kudchadker RJ, Johnson J, Choi S, Lee AK. Dosimetric Changes Resulting From Patient Rotational Setup Errors in Proton Therapy Prostate Plans. Int J Radiat Oncol Biol Phys. e-Pub 12/4/2008. PMID: 19058919.
6. Kudchadker RJ, Swanson DA, Kuban DA, Lee AK, Bruno TL, Frank SJ. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era? Int J Radiat Oncol Biol Phys 72(2):623-7, 10/1/2008. PMID: 18410998.
7. Frank SJ, Dong L, Kudchadker RJ, De Crevoisier R, Lee AK, Cheung R, Choi S, O'Daniel J, Tucker SL, Wang H, Kuban DA. Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys 71(3):813-20, 7/1/2008. PMID: 18207664.
8. O'Daniel JC, Dong L, Zhang L, Wang H, Tucker SL, Kudchadker RJ, Lee AK, Cheung R, Cox JD, Kuban DA, Mohan R. Daily bone alignment with limited repeat CT correction rivals daily ultrasound alignment for prostate radiotherapy. Int J Radiat Oncol Biol Phys 71(1):274-80, 5/1/2008. PMID: 18406891.
9. Taddei PJ, Fontenot JD, Zheng Y, Mirkovic D, Lee AK, Titt U, Newhauser WD. Reducing stray radiation dose to patients receiving passively scattered proton radiotherapy for prostate cancer. Phys Med Biol 53(8):2131-47, 4/2008. PMID: 18369278.
10. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67-74, 1/1/2008. PMID: 17765406.
11. Spiess PE, Busby JE, Jordan JJ, Steinberg JR, Bassett RL, Davuluri R, Burt K, Troncoso P, Lee AK, Taylor SH, Pisters LL. Can digital rectal examination or transrectal ultrasonography biopsy findings predict the side of nodal metastasis in prostate cancer? Urol Oncol 26(1):25-30, Jan-Feb, 1/2008. PMID: 18190826.
12. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 177(6):2151-6, 2007. PMID: 17509305.
13. de Crevoisier R, Melancon AD, Kuban DA, Lee AK, Cheung RM, Tucker SL, Kudchadker RJ, Newhauser WD, Zhang L, Mohan R, Dong L. Changes in the pelvic anatomy after an IMRT treatment fraction of prostate cancer. Int J Radiat Oncol Biol Phys 68(5):1529-36, 2007. PMID: 17544595.
14. Lee AK. Commentary on "Cancer Specific Mortality After Radiation Therapy with Short-Course Hormonal Therapy or Radical Prostatectomy in Men with Localized, Intermediate-Risk to High-Risk Prostate Cancer". The American Journal of Hematology/Oncology 6(4):19-21, 2007.
15. Zhang X, Dong L, Lee AK, Cox JD, Kuban DA, Zhu RX, Wang X, Li Y, Newhauser WD, Gillin M, Mohan R. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys 67:620-9, 2007. PMID: 17236979.
16. Zullo JR, Kudchadker R, Wu R, Lee A, Prado K. Implication of CT table sag on geometrical accuracy during virtual simulation. Med Dosim 32(4):233-6, 2007. PMID: 17980822.
17. Cheung MR, Tucker SL, Dong L, de Crevoisier R, Lee AK, Frank S, Kudchadker RJ, Thames H, Mohan R, Kuban D. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 67(4):1059-65, 2007. PMID: 17241755.
18. Melancon AD, O'Daniel JC, Zhang L, Kudchadker RJ, Kuban DA, Lee AK, Cheung RM, de Crevoisier R, Tucker SL, Newhauser WD, Mohan R, Dong L. Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer? Radiother Oncol 85(2):251-259, 2007. PMID: 17892900.
19. Newhauser W, Fontenot J, Koch N, Dong L, Lee A, Zheng Y, Waters L, Mohan R. Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate. Phys Med Biol 52(11):2937-52, 2007. PMID: 17505081.
20. Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110(7):1417-28, 2007.
21. Zhang Y, Zhang L, Zhu XR, Lee AK, Chambers M, Dong L. Reducing metal artifacts in cone-beam CT images by preprocessing projection data. Int J Radiat Oncol Biol Phys 67:924-32, 2007. PMID: 17161556.
22. Spiess PE, Lee AK, Busby J, Jordan J, Hernandez M, Troncoso P, Burt K, Merriman K, Pisters L. Surgically managed lymph node positive prostate cancer: does delaying hormone therapy worsen outcome? BJU Int 99(2):321-325, 2007.
23. Spiess PE, Lee AK, Busby JE, Jordan JJ, Hernandez M, Burt K, Troncoso P, Merriman KW, Pisters LL. Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome? BJU Int 99:321-5, 2007. PMID: 17155975.
24. Lee AK, D'Amico AV. Using prostate-specific antigen doubling time in clinical practice. BJU Int 100(2):243-240, 2007. PMID: 17511769.
25. O'Daniel JC, Dong L, Zhang L, de Crevoisier R, Wang H, Lee AK, Cheung R, Tucker SL, Kudchadker RJ, Bonnen MD, Cox JD, Mohan R, Kuban DA. Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 66:883-91, 2006. PMID: 17011461.
26. Giordano SH, Lee A, Kuo Y, Freeman J, Goodwin JS. Gastrointestinal late toxicity of radiation for prostate cancer. Cancer 107:423-32, 2006.
27. Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, Rosser CJ, Kuban DA. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 107:631-9, 2006. PMID: 16802288.
28. Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 107:275-80, 2006. PMID: 16770783.
29. Lee AK. Radiation therapy combined with hormone therapy for prostate cancer. Semin Radiat Oncol 16:20-8, 2006.
30. Lee AK, Frank SJ. Update on radiation therapy in prostate cancer. Hematol Oncol Clin North Am 20:857-78, 2006. PMID: 16861119.
31. Court LE, Dong L, Lee AK, Cheung R, Bonnen MD, O'Daniel J, Wang H, Mohan R, Kuban D. An automatic CT-guided adaptive radiation therapy technique by online modification of multileaf collimator leaf positions for prostate cancer. Int J Radiat Oncol Biol Phys 62:154-63, 2005. PMID: 15850916.
32. Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters L, Kuban DA. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61:14-9, 2005. PMID: 15629589.
33. Lee CT, Dong L, Ahamad AW, Choi H, Cheung R, Lee AK, Horne DF, Jr, Breaux AJ, Kuban DA. Comparison of treatment volumes and techniques in prostate cancer radiation therapy. Am J Clin Oncol 28:618-25, 2005. PMID: 16317275.
34. Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61:993-1002, 2005. PMID: 15752878.
35. Wang H, Dong L, Lii MF, Lee AL, de Crevoisier R, Mohan R, Cox JD, Kuban DA, Cheung R. Implementation and validation of a three-dimensional deformable registration algorithm for targeted prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 61:725-35, 2005. PMID: 15708250.
36. Rosser CJ, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology 66:327-31, 2005. PMID: 16040084.
37. Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker S, Pisters L, Babaian R, Kuban D. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 63:134-40, 2005.
38. Lee AK, Levy LB, Cheung R, Kuban D. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63:456-62, 2005. PMID: 15927415.
39. Leibovici D, Lee AK, Cheung RM, Spiess PE, Kuban DA, Rosser CJ, Shen Y, Yang Y, Chichakli R, Pisters LL. Symptomatic local recurrence of prostate carcinoma after radiation therapy. Cancer 103:2060-6, 2005. PMID: 15822114.
40. Lee AK, D'Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 23:8192-7, 2005. PMID: 16278472.

Invited Articles
1. Lee AK. Commentary on "Cancer-Specific Mortality After Radiation Therapy with Short-Course Hormonal Therapy or Radical Prostatectomy in Men with Localized, Intermediate-Risk to High-Risk Prostate Cancer". The American Journal of Hematology/Oncology 6:1-3, 2007.
2. Lee AK. Radiation therapy combined with hormone therapy for prostate cancer. Semin Radiat Oncol 16:20-8, 2006. PMID: 16378903.

Abstracts
1. Cheung MR, Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Mohan R, Kuban D, Lee AK, Cox JD. Dose-volume analyses of grade > 2 late rectal toxicity among patients treated on protocol RTOG 94-06. Int J Radiat Oncol Biol Phys 69(3):S9, 2007.
2. Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Lee AK, Cheung MR, Kuban DA, Cox JD, Mohan R. Fit of a generalized lyman normal- tissue complication probability (NTCP) model to grade > 2 late rectal toxicity date from patients treated on protocol RTOG 94-06. Int J Radiat Oncol Biol Phys 69(3):S8-S9, 2007.
3. Kudchadker R, Zhu X, Zhang L, Lee A, Mohan R, Gillin M, Dong L. Implementation of on-board imager for daily image-guided radiation therapy in a multi-vendor environment. 48th AAPM Meeting, Orlando, FL, 2007.
4. Lee AK, Kudchadker RJ, Amos RA, Johnson JL, Choi SL, Kuban DA, Cox JD, Mohan R, Gillin M, Dong L. Proton Therapy vs. IMRT for prostate cancer: A dosimetric comparison. Int J Radiat Oncol Biol Phys 69(3):S342, 2007.
5. Johnson J, Lee A, Kudchadker R, Amos R, Frank S, Cheung R, Kuban D, Dong L. Comparison of prostate implanted fiducials with CT and ultrasound for prostate target localization: Initial results. 48th AAPM Meeting, Orlando, FL, 2006.
6. O'Daniel J, Dong L, Zhang L, Wang L, Tucker S, Kudchadker R, de Crevoisier R, Lee A, Cheung R, Cox J, Kuban D, Mohan R. Dosimetric comparison of the no action level alignment techniques for prostate cancer. AAPM Meeting, Orlando, FL, 2006.
7. Cheung R, Tucker S, de Crevoisier R, Lee A, Frank S, Kudchadker R, Thames H, Mohan R, Kuban D. Identification of the bladder dose and volume constraints to control late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 66:S37-38 (#64), 2006.
8. Zullo J, Kudchadker R, Wu R, Lee A, Prado K. Implication of CT Couch Sag on geometrical accuracy during virtual simulation. 48th AAPM, Orlando, FL, 2006.
9. Kuban D, Tucker S, Dong L, Huang E, Lee A, Cheung R. Long-term results of a randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 66:S8-9 (#15), 2006.
10. Frank SJ, Pisters LL, Davis J, Lee AK, Cheung R. Quality of life after monotherapy treatment for localized prostate cancer: implant (i-125), radical prostatectomy, and high dose external beam radiation therapy. Int J Radiat Oncol Biol Phys 66:S131 (#1005), 2006.
11. Melancon A, Dong L, de Crevoisier R, O'Daniel J, Kudchadker R, Newhauser W, Tucker S, Lee A, Cheung R, Cox J, Mohan R, Kuban D. The dosimetric impact of intrafractional motion on IMRT treatment of Prostate Cancer. 48th AAPM Meeting, Orlando, FL, 2006.
12. Lee AK, Dohadwala M, Ballo M. The clinical impact of local radiation therapy and the percentage of positive lymph nodes in prostate cancer patients treated with hormonal therapy. Int J Radiat Oncol Bio Phys Supplement, ASTRO 63:S194, 2005.

Last updated: 8/28/2009